After being one of the companies dominating the news through COVID, Pfizer has crashed to earth with a bump similar to many of the ASX lithium stocks – a great example of euphoric trades being volatile, and sometimes worse. PFE traded around 4% higher overnight after the biopharmaceutical company’s 2025 outlook met expectations; the market was clearly getting used to disappointment. Pfizer expects revenue to come between $US61 billion and $64 billion next year, on par with the consensus estimate of $US63.2 billion. As the world moves on from COVID, Pfizer is focusing on cost-cutting measures and strategic investments in its drug pipeline, particularly in oncology, to drive future growth and mitigate the impact of revenue losses from patent expirations (allowing cheap generic competition).
- We can see PFE US bouncing back towards $US30, aided by the fact its trading on the cheap side compared to historical valuations.
